SBIR/STTR Research Award
In-Situ Autovaccination against Solid Cancers with Intratumoral Hiltonol (Poly-IC
Award amount
$225,000Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Oncovir
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- G6DHYDBSZQU4
- Solicitation number
- PA13-234
- Topic code
- NCI
Research abstract
DESCRIPTION (provided by applicant): Hiltonol (poly-ICLC) is a stabilized dsRNA therapeutic viral mimic or 'danger signal' that activates multiple elements of innate and adaptive immunity. It is a standalone immunomodulator, but when properly combined with antigen it generates a comprehensive Th-1 weighted immune response best suited for antiviral and antitumor action. This project will combine Hiltonol with cancer patients' own tumor antigens in-situ to generate a comprehensive systemic immune response against the tumor and its metastases. Objectives: 1) To determine the safety of intratumoral (IT) Poly-ICLC. 2) To explore efficacy as manifested by irRC defined disease control and progression-free survival at 26 weeks. Secondary objectives are overall survival and immunologic response in blood and tumor biopsy, including immunoscore. Indications/Tumor groups: 1) Unresectable stage 3b, 3c or IV, M1a or M1b melanomas that are accessible to IT injections 2) Unresectable head and neck cancers that are ac
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- In Situ Autovaccination against Solid Cancers with Intratumoral Hiltonol Poly ICLC A phase II Adaptive Multicenter Clinical Study
- Hiltonol provides potent neuroprotection from ischemic brain injury in stroke.
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment
- Development of small molecule therapeutics targeting AR-V7 for prostate cancer
- Decentralized Clinical Trial of Effectiveness of EnergyPoints App to Guide Acupressure Use for Fatigue and Sleep Disturbances in Cancer Survivors
- Optimized targeted radiotherapy of pancreatic cancer
- Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis
Research funding history
3 SBIR/STTR records share this UEI (2013–2016). Reported award amounts total $1,946,722. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services